Immunotherapy Advances in Multiple Myeloma

1:04:00
 
Share
 

Manage episode 177361974 series 1143960
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.
Recent years have seen the emergence of immunotherapy as a leading form of treatment for multiple myeloma. New strategies such as monoclonal antibody therapies. antibody-drug conjugates, immune checkpoint therapy, adoptive cell therapies such as natural killer cells, marrow infiltrating lymphocytes, dendritic cells, CAR T cell therapies and cancer vaccines represent the basis for next generation myeloma therapies. We are talking to Dr. Saad Usmani of Levine Cancer Institute / Carolinas Healthcare System about the latest advances in immunotherapy for multiple myeloma. Dr. Saad Z. Usmani MD, is a clinical associate professor of medicine at the UNC-Chapel Hill School of Medicine, director of the plasma cell disorder program at Levine Cancer Institute, as well as the director of clinical research in hematologic malignancies at the Levine Cancer Institute/Carolinas Healthcare System. Dr. Saad Usmani received his medical education at Allama Iqbal Medical College Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan, and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut. Dr. Usmani’s clinical and translational research has been focused on plasma cell disorders, specifically high-risk multiple myeloma. Panel members - Gary Petersen, Yelak Biru, Cynthia Chmielewski, Priya Menon RSVP here.

165 episodes available. A new episode about every 20 days averaging 60 mins duration .